Search
Ultragenyx Pharmaceutical Inc
RAREAdd to Watchlist
24.910USD
-1.130-4.34%
Close 07-31 16:00（ET）Quotes delayed by 15 min
2.45BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Ultragenyx Pharmaceutical Inc is 8.42, ranking 36 out of 155 in the Pharmaceuticals industry. The average price target is 78.50, with a high of 128.00 and a low of 35.00.
Analyst Rating
Based on
19
analysts
Buy
Current Rating
52.056
Target Price
+108.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Ultragenyx Pharmaceutical Inc
RARE
19
Biogen Inc
BIIB
38
Amgen Inc
AMGN
38
Eli Lilly and Co
LLY
35
Pfizer Inc
PFE
32
AbbVie Inc
ABBV
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Ultragenyx Pharmaceutical Inc's expected revenue for the next quarter?
Ultragenyx Pharmaceutical Inc's expected revenue is 180.24M.
What is Ultragenyx Pharmaceutical Inc's price target?
Analysts forecast that Ultragenyx Pharmaceutical Inc's price target is USD 78.50, with the highest forecast at USD 128.00 and the lowest forecast at USD 35.00.
How have Ultragenyx Pharmaceutical IncRARE's recent earnings per share performed?
The market expectation was USD -1.84, while Ultragenyx Pharmaceutical IncRARE's earnings per share (EPS) for the previous quarter was USD -1.29. EPS for the next quarter is expected at USD -1.23.
What is the analyst rating for Ultragenyx Pharmaceutical Inc?
Based on the ratings of Ultragenyx Pharmaceutical Inc's stock from 19 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.